Hong Kong, 18th June 2024 - Hong Kong Centre for Cerebro-cardiovascular Health Engineering (COCHE) has announced a strategic partnership with the VTech Communications Limited, the number one electronic manufacturing services (EMS) provider in Hong Kong. By drawing on COCHE’s accumulation of research and development in the prevention and treatment technology for cerebro-cardiovascular diseases, and VTech’s expertise in New Product Introduction (NPI) and manufacturing, the partnership aims to accelerate the development and commercialization of innovative devices for early detection of cardiovascular diseases.
Mr. Andy Leung Hon Kwong, Executive Director of VTech Group and CEO of VTech Contract Manufacturing Services (Left), officiated the MOU Signing Ceremony together with Prof. Kannie Wai Yan Chan, Director of Hong Kong Centre for Cerebro-Cardiovascular Health Engineering (COCHE), Professor in Department of Biomedical Engineering and Associate Dean (Internationalisation & Outreach) in College of Engineering of City University of Hong Kong (Right)
Established in 2020 under the City University of Hong Kong, in collaboration with University of Oxford and Karolinska Institutet, COCHE is a leading medical research and development centre. Its research areas encompass Wearable Intelligent Sensor Engineering and Bioinstrumentation, Multi-Modal Medical and Molecular Imaging, and Human Intelligence and AI Integration, with a focus on innovative wearables that collect continuous key vital signs in real time. This is paving the way for early detection and diagnosis of possible cardiovascular diseases, which are the leading cause of death globally.
VTech is one of the world’s top 50 EMS providers and its cutting-edge manufacturing facilities are moving towards Industry 4.0 manufacturing. Its NPI Centre, established in 2020, has a well-established reputation for turning innovative ideas into marketable products for production at scale.
The collaboration framework encompasses not only the collaborative development of medical devices for cerebro-cardiovascular diseases, spanning from product development, prototype design to mass production, but also involves a range of exchange initiatives such as seminars, workshops, and training programs. These initiatives are designed to enhance the professional capabilities of both teams and facilitate the practical implementation of research transformation results.
Through this strategic partnership, both parties aim to expedite the commercialization process of innovative diagnostic and treatment technologies for cerebro-cardiovascular diseases. By striving to enhancing the technical proficiency and utilization of associated medical devices, the both parties will try to offer more precise and efficient technical solutions, for the early surveillance, detection, prevention, and management of cardiovascular and cerebrovascular ailments for patients globally.
Comments